Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 15, 2025 08:00 ET | Source: Relmada Therapeutics

Relmada Therapeutics Appoints Renowned Urologic Oncologist, Yair Lotan, MD, to Chair the Clinical Advisory Board and Support Development of NDV-01

Dr. Lotan’s distinguished expertise in bladder cancer care and clinical development brings further scientific acumen to Relmada’s NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 ...
June 17, 2025 07:00 ET | Source: Relmada Therapeutics

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

Dr. Pruthi brings vast clinical development experience advancing novel therapies for NMIBC to Relmada and the NDV-01 program Phase 3 trial for NDV-01 expected to begin in H1 2026 ...
May 12, 2025 16:01 ET | Source: Relmada Therapeutics

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Positive initial Phase 2 proof-of-concept data for NDV-01 at AUA 2025 showing a 90% overall response rate at any time in non-muscle invasive bladder cancer (US prevalence 600K patients) The Phase 2...
May 08, 2025 07:30 ET | Source: Relmada Therapeutics

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

CORAL GABLES, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, or “the Company”), a clinical-stage biotechnology company committed to advancing innovative...
April 28, 2025 13:38 ET | Source: Relmada Therapeutics

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

90% of patients achieved high grade disease-free status at any time point with NDV-01, demonstrating strong proof-of-concept for sustained-release “GEM/DOCE” formulation* NDV-01 showed promising...
April 27, 2025 09:00 ET | Source: Relmada Therapeutics

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

CORAL GABLES, Fla., April 27, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation...
April 24, 2025 08:00 ET | Source: Relmada Therapeutics

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

April 28th AUA data presentation to highlight study in patients with high-grade non-muscle invasive bladder cancer (HG-NMIBC) Virtual event to be held on April 28, 2025 at 4:30 PM ET CORAL GABLES,...
April 14, 2025 08:41 ET | Source: Relmada Therapeutics

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation...
April 14, 2025 07:30 ET | Source: Relmada Therapeutics

Relmada Therapeutics To Present NDV-01 Data at AUA2025

CORAL GABLES, Fla., April 14, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”, “the Company”), a clinical-stage biotechnology company, today announced the presentation...
March 27, 2025 16:05 ET | Source: Relmada Therapeutics

Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer (HG-NMIBC), to be presented at AUA 2025 in April Advancing novel neurosteroid, sepranolone, towards Phase 2b...